SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) August 26, 1996
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
On August 26, 1996, Biocontrol Technology, Inc.
(NASDAQ:BICO) announced that 34 production models of
its Diasensor 1000 noninvasive glucose sensor for
diabetics are completed. The Company is currently
revising its 510(k) submission and, although there can
be no assurances, plans to resubmit it to the Food and
Drug Administration (FDA) within 30 days.
The Company further stated that in September it
will begin a series of visits to its Indiana, PA
facilities by potential corporate partners and
investment banking groups.
BICO has also produced a video walk-through tour
of its R&D, manufacturing, and Calibration Centers.
The video shows a patient being tested on the Diasensor
1000, and discusses the current status and future plans
of the Diasensor 1000 project. The video is available
from the Company by contacting their Public Relations
or Investor Relations Depts.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information
and Exhibits.
(a) Financial Statements and Businesses Acquired - Not
Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits-Press Release
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: August 26, 1996
